Cited by 264Pancreatic function and diabetesDiabetes and associated disordersDiabetes Treatment and Management

Is reduced first-phase insulin release the earliest detectable abnormality in individuals destined to develop type 2 diabetes?

Gerich, John E.·2002·Diabetes

Abstract

Insulin is released from the pancreas in a biphasic manner in response to a square-wave increase in arterial glucose concentration. The first phase consists of a brief spike lasting approximately 10 min followed by the second phase, which reaches a plateau at 2-3 h. It is widely thought that diminution of first-phase insulin release is the earliest detectable defect of beta-cell function in individuals destined to develop type 2 diabetes and that this defect largely represents beta-cell exhaustion after years of compensation for antecedent insulin resistance. In this article, the origins of these concepts are reviewed and recent evidence is presented suggesting that reductions in both phases of insulin release are equally early, that they precede insulin resistance other than that simply due to obesity, and that they therefore may represent the primary genetic risk factor predisposing individuals to type 2 diabetes.

Integrity signals

Registry

Crossref · 10.2337/diabetes.51.2007.s117

Cites

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

No citation lists for this paper

No citation lists for this paper yet — checked again daily.

References 33 · Cited by 264

Authors
Gerich, J. E.
Affiliations
University of Rochester Medicine (US)
Corresponding author
Gerich, John E.
Venue
Diabetes
Published
2002-02-01
Volume
51
Issue
suppl_1
Pages
S117-S121
ISSN
  • 0012-1797 (ISSN-L)
  • 1939-327X
OpenAlex
W2109438832
Cited by
264
References
33
Citations by year
2026: 5 · 2025: 4 · 2024: 12 · 2023: 14 · 2022: 15 · 2021: 16 · 2020: 11 · 2019: 14 · 2018: 6 · 2017: 13 · 2016: 19 · 2015: 13 · 2014: 20 · 2013: 11 · 2012: 15
FWCI
1.79
Type
journal article
Language
en
Open access
closed
Locations
  • Diabetes (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • World Health Organization
  • National Institute of Diabetes and Digestive and Kidney Diseases (DK-20411)
  • National Center for Research Resources (5-M01-RR-00044, M01RR000044)
Topics
  • Health Sciences › Medicine › Surgery › Pancreatic function and diabetes
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Diabetes and associated disorders
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
Keywords
first-phase insulin release, type 2 diabetes, beta-cell function, beta-cell exhaustion, insulin resistance, genetic risk, obesity, glucose tolerance, pancreatic beta cells
MeSH terms
Diabetes Mellitus, Type 2, Humans, Insulin, Islets of Langerhans

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review